Show summary Hide summary
The U.S. Food and Drug Administration has approved Auvelity as the first non-antipsychotic medication specifically indicated to treat agitation in people with Alzheimer’s disease, a move regulators say adds a new clinical option for a common and often disruptive symptom. The decision, announced this week, extends the drug’s use beyond its 2022 approval for major depressive disorder and brings fresh choices for clinicians and caregivers managing behavioral complications of dementia.
Why this matters now
Agitation — which can include restlessness, shouting, pacing or aggressive behavior — affects a large share of people with Alzheimer’s and frequently drives decisions to increase supervision or seek institutional care. A formally approved, non-antipsychotic option could change prescribing patterns, reduce reliance on drugs with heavy sedation or cardiac risks, and alter daily care for patients and families.
Wall Street rally stalls after AI sell-off and oil surge
College sports gambling crisis grows: Brendan Sorsby case underscores risks
What the evidence showed
The FDA cited two randomized clinical trials that formed the basis for the expanded indication. In a short-term trial lasting five weeks, caregivers reported reductions in the frequency and severity of agitated behaviors among patients taking Auvelity compared with placebo.
The second study examined relapse prevention: patients who initially responded to treatment were randomized to continue the medication or switch to placebo. Those who stayed on the active drug experienced a longer time before symptoms returned, supporting the drug’s role in maintaining symptom control.
Auvelity is produced by Axsome Therapeutics and is given as rapid-onset extended-release tablets.
How the drug works and what clinicians should watch for
Auvelity targets multiple neural pathways, including effects at the NMDA and sigma-1 receptors, a mechanism thought to influence both agitation and mood symptoms in older adults with dementia.
- Key monitoring: Screen for a history of bipolar disorder, check blood pressure regularly, and review all medications for existing bupropion or dextromethorphan to avoid duplicative exposure.
- Common side effects: dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction and excessive sweating.
- Serious risks: dose-related seizure risk, potential blood pressure increases and the possibility of mania in vulnerable patients.
- Mental health warning: product labeling notes a risk of increased suicidal thoughts in younger adults; clinicians should monitor mood and behavior closely after starting or changing dose.
Regulators stressed that, while the drug offers an alternative to antipsychotics, it is not risk-free. The label includes dose and safety guidance intended to limit adverse outcomes in older and medically complex patients.
Voices from regulators and clinicians
An FDA official described the approval as a meaningful step in addressing one of the most challenging symptoms of Alzheimer’s, noting the potential benefit to both patients and caregivers. The agency’s drug review director highlighted the positive results from the two randomized trials as the basis for the expanded use.
A practicing geriatric psychiatrist interviewed about the approval said many clinicians may prefer Auvelity over antipsychotics in appropriate cases because it tends to cause less sedation and may carry fewer cardiac side effects, making it easier to tolerate in very elderly patients. Still, the clinician emphasized the need to individualize treatment and follow safety recommendations closely.
Axsome Therapeutics, the manufacturer, will be responsible for post-approval monitoring and for providing updated prescribing information as more real-world data become available.
For families and providers, the approval adds a new tool for managing agitation in Alzheimer’s, but it comes with the familiar balance of potential benefit and measurable risk. Ongoing surveillance and careful patient selection will determine how broadly the drug is adopted in routine care.
